Skip to content

Menu

LexBlog, Inc. logo
NetworkSub-MenuBrowse by SubjectBrowse by PublisherJoin the NetworkGet StartedSubscribeSupport
Contact Us
Search
Close

FTC Forms Task Force to Investigate Healthcare Transactions, Deceptive Marketing

By Norton Travis & Emily Manning on March 26, 2026
Email this postTweet this postLike this postShare this post on LinkedIn

On March 20, the Federal Trade Commission (FTC) issued a memorandum announcing the formation of a Healthcare Task Force dedicated to addressing unlawful business practices within the healthcare sector. The memorandum emphasizes that industry consolidation and anticompetitive conduct have contributed to “higher prices, decreased quality, less access and transparency, and stifled innovation.” According to the FTC, these practices weaken incentives to control costs and enhance care delivery, with adverse effects on patients and communities.

The task force will operate as a coordinated initiative across multiple FTC divisions, including the Bureau of Competition, Bureau of Consumer Protection, Bureau of Economics, Office of Policy Planning, and Office of Technology. Its mandate includes advancing targeted enforcement and advocacy efforts, developing agency-wide investigative strategies, and proactively identifying opportunities to shape legal outcomes through amicus briefs and statements of interest.

The memorandum also highlights numerous recent enforcement actions, including the FTC’s effort to block the proposed merger between Alcon and Lensar involving femtosecond laser-assisted cataract surgery technology. The FTC also took action against substance-abuse treatment providers and other companies that allegedly used deceptive practices to market health plans, weight-loss programs, and consumer products.

While there were earlier indications that the current administration would be taking a less aggressive approach toward healthcare transactions, this action by the FTC demonstrates that’s not likely. In light of these developments, healthcare providers and companies should anticipate a more rigorous and coordinated enforcement posture, with particular focus on transactions, pricing practices, and consumer-facing representations. Stakeholders should consider proactively assessing compliance frameworks and business strategies to be able to demonstrate pro-consumer rationales to mitigate regulatory risk.

Sign up to receive Rivkin Rounds at www.RivkinRounds.com.

Photo of Norton Travis Norton Travis
Email
Photo of Emily Manning Emily Manning
Email
  • Posted in:
    Health Care and Life Sciences
  • Blog:
    Rivkin Rounds
  • Organization:
    Rivkin Radler
  • Article: View Original Source

Call us at 1-800-913-0988 or email sales@lexblog.com.

Facebook LinkedIn Twitter RSS
  • About LexBlog
  • The Field We Built
  • Our Beliefs
  • Our Team
  • Contact LexBlog
  • Disclaimer
  • Editorial Policy
  • Terms of Service
  • Get Started
  • Publishing Solutions
  • Compass
  • Submit a Request
  • Support Center
  • System Status
Copyright © 2026, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo